China's Sinovac Says HFM Vaccine's Final Trial Showed Success In Tots
This article was originally published in PharmAsia News
Executive Summary
Sinovac Biotech said a Phase III trial of its Enterovirus 71 vaccine was successful in preventing hand, foot and mouth disease infection in babies between the ages of 6 to 35 months of age.